Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | GPR3 | P46089 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
| ▸ | PRKCI | P41743 | 1/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9350114 | 0.73 | KDM4E (0.39) | KDM4EGPR3ALDH1A1PARP1PRKCI | |
| SCHEMBL976367 | 0.71 | KDM4E (0.40) | KDM4EGPR3MAPK1ALDH1A1PARP1 | |
| SCHEMBL30343302 | 0.70 | KDM4E (0.39) | KDM4EGPR3TDP1 | |
| SCHEMBL8322283 | 0.67 | KDM4E (0.42) | KDM4EGPR3MAPK1ALDH1A1PARP1 | |
| SCHEMBL18576434 | 0.63 | KDM4E (0.47) | KDM4EGPR3MAPK1ALDH1A1PARP1 | |
| SCHEMBL6622101 | 0.63 | KDM4E (0.39) | KDM4EGPR3MAPK1 | |
| SCHEMBL1537127 | 0.63 | KDM4E (0.39) | KDM4EGPR3MAPK1 | |
| SCHEMBL29521297 | 0.63 | HPRT1 (0.47) | KDM4EMAPK1ALDH1A1HSD17B10TDP1 | |
| SCHEMBL6201471 | 0.63 | ALOX5 (0.38) | KDM4EMAPK1ALDH1A1HSD17B10TDP1 | |
| SCHEMBL28080700 | 0.62 | KDM4E (0.38) | KDM4EGPR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1797098-B1 | 3-OXA-10-AZA-PHENANTHRENES AS PDE4 OR PDE3/4 INHIBITORS | NYCOMED GMBH (DE) | 2011-05-04 | — | — | EP | disclosed |
| US-7838521-B2 | 3-oxa-10-aza-phenanthrenes | NYCOMED GMBH (DE) | 2010-11-23 | — | — | US | disclosed |
| US-7838521-B2 | 3-oxa-10-aza-phenanthrenes | NYCOMED GMBH (DE) | 2010-11-23 | — | — | US | disclosed |
| US-20070259868-A1 | Novel 3-Oxa-10-Aza-Phenanthrenes | ALTANA PHARMA AG (DE) | 2007-11-08 | — | — | US | disclosed |
| US-20070259868-A1 | Novel 3-Oxa-10-Aza-Phenanthrenes | ALTANA PHARMA AG (DE) | 2007-11-08 | — | — | US | disclosed |
| EP-1797098-A2 | 3-OXA-10-AZA-PHENANTHRENES AS PDE4 OR PDE3/4 INHIBITORS | Altana Pharma AG (DE) | 2007-06-20 | — | — | EP | disclosed |
| WO-2006027344-A2 | 3-OXA-10-AZA-PHENANTHRENES AS PDE4 OR PDE3/4 INHIBITORS | ALTANA PHARMA AG (DE) | 2006-03-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259868-A1 | Novel 3-Oxa-10-Aza-Phenanthrenes | PDE4A, PDE4B, PDE3A | KDM4E 55/4885GPR3 414/4885MAPK1 1390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.